MNPR Monopar Therapeutics

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that its abstract on camsirubicin submitted to the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting has been selected for a poster presentation. CTOS 2022, held in Vancouver, Canada, brings together the world’s leading sarcoma specialists. Monopar’s poster will be the first formal release of data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma (ASTS) patients.

“We are looking forward to sharing data from our dose-escalating camsirubicin study with leading sarcoma specialists from around the world in a little over a month,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

Meeting Details:

Event: Connective Tissue Oncology Society (CTOS) Annual Meeting Conference

Date: November 16-19, 2022

Location: Vancouver Convention Centre, Vancouver, BC, Canada

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: .

CONTACT:  

Monopar Therapeutics Inc.

Investor Relations  

Kim R. Tsuchimoto  

Chief Financial Officer  

Follow Monopar on social media for updates: 

Twitter:   LinkedIn:

 



EN
12/10/2022

Underlying

MNPRMonopar Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Monopar Therapeutics

 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and...

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in collaboration with Excel Diagnostics and Nuclear Oncology Center (“EDNOC”), a premier diagnostic medical imaging and therapeutic nuclear medicine center, today announced that the physician-sponsored Expanded A...

June 11, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russ...

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025. The inclusion follows the initial announcement on Friday, May...

June 3, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Reports First Quarter 2025 Financial Results and ...

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Assoc...

May 13, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar’s late-breaker p...

May 7, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation...

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congre...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch